Jane Osbourn, who contributed to the development of phage display technology, has been appointed chair of the board of Mogrify Ltd, which has developed a proprietary direct cellular conversion technology. In addition she will be a member of the company’s scientific advisory board. Dr Osbourn has more than 30 years’ experience in biologics discovery and development, most recently as vice president for research and development at MedImmune (AstraZeneca Plc). Dr Osbourn is also chair of the BioIndustry Association, a director of Babraham Bioscience Technologies and a director of Cambridge Enterprise.
Mogrify announced the appointment on 9 September 2019.
Copyright 2019 Evernow Publishing Ltd